Document Detail

Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.
MedLine Citation:
PMID:  22252452     Owner:  NLM     Status:  MEDLINE    
In the gut of patients with Crohn's disease (CD), high Smad7 blocks the immune-suppressive activity of transforming growth factor (TGF)-β1, thereby contributing to amplify inflammatory signals. In vivo in mice, knockdown of Smad7 with a Smad7 antisense oligonucleotide (GED0301) attenuates experimental colitis. Here, we provide results of a phase 1 clinical, open-label, dose-escalation study of GED0301 in patients with active, steroid-dependent/resistant CD, aimed at assessing the safety and tolerability of the drug. Patients were allocated to three treatment groups receiving oral GED0301 once daily for 7 days at doses of 40, 80, or 160 mg. A total of 15 patients were enrolled. No serious adverse event was registered. GED0301 was well tolerated and no patient dropped out during the study. Twenty-five adverse events were documented in 11 patients, the majority of whom were judged to be of mild intensity and unrelated to treatment. GED0301 treatment reduced the percentage of inflammatory cytokine-expressing CCR9-positive T cells in the blood. The study shows for the first time that GED0301 is safe and well tolerated in patients with active CD.
Giovanni Monteleone; Massimo C Fantini; Sara Onali; Francesca Zorzi; Giulia Sancesario; Sergio Bernardini; Emma Calabrese; Francesca Viti; Ivan Monteleone; Livia Biancone; Francesco Pallone
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-01-17
Journal Detail:
Title:  Molecular therapy : the journal of the American Society of Gene Therapy     Volume:  20     ISSN:  1525-0024     ISO Abbreviation:  Mol. Ther.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-04-04     Completed Date:  2013-02-20     Revised Date:  2014-05-28    
Medline Journal Info:
Nlm Unique ID:  100890581     Medline TA:  Mol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  870-6     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Crohn Disease / therapy*
Flow Cytometry
Middle Aged
Oligonucleotides, Antisense / administration & dosage,  therapeutic use*
Smad7 Protein / genetics,  metabolism*
Young Adult
Reg. No./Substance:
0/Oligonucleotides, Antisense; 0/SMAD7 protein, human; 0/Smad7 Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Action and reaction: the biological response to siRNA and its delivery vehicles.
Next Document:  Retroviral integrations in gene therapy trials.